Replies to post #163846 on Biotech Values

[jq1234]

GILD didn't use an active comparator in any of their late-stage studies.

What do you mean? This study is Sofosbuvir plus Ribavirin. Their current NDA for treatment naive GT2/3 came from pivotal study FISSION Sofosbuvir plus Ribavirin for 12 weeks vs Pegylated interferon and ribavirin.